# Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

> **NCT03541902** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Malignant Neoplasms of Urinary Tract
- Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions
- Sarcomatoid Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8
- Unclassified Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT03541902
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-15
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541902, "Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03541902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*